**In the Claims:**

This listing of claims will replace all prior versions and listings of the claims in this application.

**Listing of Claims**

1. (Currently Amended) A pharmaceutical composition comprising a polyglucose or a mixture of polyglucose molecules, and[[,]] optionally, salts thereof and sorbic acid, or a salt thereof.[[.]]

2. (Currently Amended) [[A]] The pharmaceutical composition according to claim 1, wherein the composition is non-sensitizing ~~which is non-sensitising~~ when applied topically intravaginally, rectally, ~~or~~ to the penis, ~~or~~ to areas around or on the genitalia, to the genito urinary tract and/or to the rectum.

3. (Currently Amended) [[A]] The pharmaceutical composition according to ~~either~~ claim 1, ~~or 2 which~~ wherein the composition is effective against Gram positive bacteria, Gram negative bacteria, yeasts and/or molds ~~moulds~~.

4. (Currently Amended) [[A]] The pharmaceutical composition according to ~~any preceding~~ claim 1, wherein the sorbic acid salt is an alkali metal or alkali earth metal salt.

5. (Currently Amended) [[A]] The pharmaceutical composition according to claim 4, wherein the salt is a potassium or calcium salt.

6. (Currently Amended) [[A]] The pharmaceutical composition according to ~~any preceding~~ claim 1, wherein the sorbic acid, or a salt thereof, is the trans-trans form.

7. (Currently Amended) [[A]] The pharmaceutical composition according to ~~any preceding~~ claim 1, wherein the sorbic acid, or a salt thereof is present in an amount of from 0.01 to 1.0% w/w.

8. (Currently Amended) [[A]] The pharmaceutical composition according to ~~any preceding~~ claim 1, wherein the composition is buffered to vaginal pH.

9. (Currently Amended) [[A]] The pharmaceutical composition according to claim 8, wherein the composition is buffered to a pH of from 3.8 to 4.5.

10. (Currently Amended) [[A]] The pharmaceutical composition according to ~~any preceding~~ claim 1 further comprising ~~including~~ a buffering agent.

11. (Currently Amended) [[A]] The pharmaceutical composition according to claim 10, wherein the buffering agent is lactic acid.

12. (Currently Amended) [[A]] The pharmaceutical composition according to ~~either~~ claim 10, ~~or 11~~ wherein the buffering agent is present in an amount of from 0.01 to 1.0% w/w.

13. (Currently Amended) [[A]] The pharmaceutical composition according to ~~any preceding~~ claim 1, wherein the composition is formulated in an aqueous gel, ~~or~~ gel or powder form.

14. (Currently Amended) [[A]] The pharmaceutical composition according to ~~any preceding~~ claim 1, wherein the polyglucose, or a salt thereof, is present in an amount of at least 1 μg/ml and up to $10^5$ μg/ml.

15. (Currently Amended) [[A]] The pharmaceutical composition according to ~~any preceding~~ claim 1, wherein the composition ~~is made up in~~ comprises a unit dosage form comprising from 1 to 10 ml of the composition.

16. (Currently Amended) [[A]] The pharmaceutical composition according to ~~any preceding~~ claim 1, wherein the polyglucose polymer is a salt.

17. (Currently Amended) [[A]] The pharmaceutical composition according to claim 16, wherein the salt is an anionic salt.

18. (Currently Amended) [[A]] The pharmaceutical composition according to ~~any preceding~~ claim 1, wherein the polyglucoses are dextrins, or salts thereof.

19. (Currently Amended) [[A]] The pharmaceutical composition according to claim 18, wherein the salt is a sulphate.

20. (Currently Amended) [[A]] The pharmaceutical composition according to claim 19, wherein the polyglucose is a dextrin sulphate.

21. (Currently Amended) [[A]] The pharmaceutical composition according to claim 20, wherein the dextrin sulphate comprises ~~contains~~ at most two sulphate groups per unit.

22. (Currently Amended) [[A]] The pharmaceutical composition according to claim 19, ~~any of claims 19 to 21~~ wherein the glucose units of the dextrin are substituted in one or more of the 2, 3 and 6 positions by sulphate groups.

23. (Currently Amended) [[A]] The pharmaceutical composition according to claim 22, wherein a substantial proportion of the sulphate groups are in the 2-position.

24. (Currently Amended) [[A]] The pharmaceutical composition according to claim 23, wherein greater than 70% of the sulphate groups are in the 2-position.

25. (Currently Amended) [[A]] The pharmaceutical composition according to ~~any preceding~~ claim 1, wherein up to 60% by weight of the polyglucose has a D.P. less than 12.

26. (Currently Amended) [[A]] The pharmaceutical composition according to ~~any preceding~~

claim 1, wherein the polyglucose contains at least 50% by weight of glucose polymers of D.P. greater than 12.

27. (Currently Amended) [[A]] The pharmaceutical composition according to claim 26, wherein the polyglucose ~~contains~~ comprises less than 10% by weight of glucose polymers having a D.P. less than 12.

28. (Currently Amended) [[A]] The pharmaceutical composition according to ~~any preceding~~ claim 1, wherein the polyglucose contains little or no material with a high molecular weight.

29. (Currently Amended) [[A]] The pharmaceutical composition according to claim 28, wherein the polyglucose contains little or no material with a molecular weight greater than 40,000.

30. (Currently Amended) [[A]] The pharmaceutical composition according to claim 13, wherein the composition is a gel and is administered in a prophylactic device.

31. (Currently Amended) [[A]] The pharmaceutical composition according to claim 30, wherein the prophylactic device is a condom.

32. (Currently Amended) [[A]] The pharmaceutical composition according to ~~any preceding~~ claim 1, wherein the composition comprises an inert carrier or diluent.

33. (Currently Amended) [[A]] The pharmaceutical composition according to ~~any preceding~~ claim 1, wherein the composition is an agent for use in the treatment of HIV-1 and related viruses or other sexually transmitted diseases.

34. (Currently Amended) [[A]] The pharmaceutical composition according to claim 1, wherein the composition is formulated for enteral or parenteral administration ~~adapted to be~~

~~administered enterally (including orally) or parenterally~~.

35. (Currently Amended) A method of treating, alleviating or preventing ~~The use of sorbic acid or a salt thereof in the manufacture of a composition comprising a polyglucose or a mixture of polyglucoses and, optionally, salts thereof for the treatment, alleviation or prevention of~~ HIV-1 or a related virus or other sexually transmitted diseases, comprising administering a composition of claim 1.

36. (Canceled)

37. (Currently Amended) The method ~~use~~ according to ~~either~~ claim 35, ~~or 36~~ wherein the composition is suitable for topical administration.

38. (Currently Amended) The method ~~use~~ according to claim 37, wherein the topical administration comprises administration in, around or on the genitalia, the genito urinary tract and/or the rectum.

39. (Currently Amended) The method ~~use~~ according to claim 38, wherein the composition is suitable for intravaginal administration, penile administration or rectal administration.

40. (Currently Amended) The method ~~use~~ according to ~~either~~ claim 35, ~~or 36~~ wherein the composition is suitable for the treatment of ~~any~~ an STD or combination of STDs.

41. (Currently Amended) The method ~~use~~ according to claim 40, wherein the STD comprises ~~is one or more of~~ bacterial vaginosis, chlamydia, genital herpes, genital warts, gonorrhea ~~gonorrhoea~~, syphilis, trichomoniasis, ~~and~~ *Candida* and combinations thereof.

42. (Currently Amended) The method ~~use~~ according to ~~either~~ claim 35, ~~or 36~~ wherein the method further ~~treatment, alleviation or prevention~~ comprises administering from 1 to 10 ml of

the composition.

43. (Currently Amended) The method ~~use~~ according to ~~either~~ claim 35, ~~or 36~~ wherein the polyglucose, or a salt thereof, is present in an amount of at least 1 μg/ml and up to $10^5$μg/ml.[[.]]

44. (Currently Amended) The method ~~use~~ according to claim 35, ~~any of claims 35 to 43~~ wherein the method ~~treatment, alleviation or prevention~~ comprises administering the composition prior to ~~immediately before or shortly before~~ sexual activity.